Antiviral Research

Interaction of the HIV fusion inhibitor AR177 (Zintevir) with the HIV type 1 second receptor
pp. 41-41(1)
Authors: Este J.A.; Proost P.; Struyf S.; Wuyts A.; Van Damme J.; De Clercq E.; Schols D.

Synthesis, anti-HIV and anti-HBV activities of novel oxaselenolane nucleosides
pp. 41-41(1)
Authors: Chu C.K.; Du J.F.; Surzhykov S.; Lin J.-S.; Newton M.G.; Cheng Y.-C.; Schinazi R.F.

Molecular Properties of HIV-1 Resistant to (+)-Enantiomers and Racemates of Oxathiolane Cytosine Nucleosides and their Potential for the Treatment of HIV and HBV Infections.
pp. 42-42(1)
Authors: Schinazi R.F.; McMillan A.; Lloyd R.L.; Schlueter-Wirtz S.; Liotta D.C.; Chu C.K.

From carbovir to 1592.
pp. 42-42(1)
Authors: Vince R.; Parker W.B.; Shannon W.M.

Identification of the Antiviral Nucleoside Drug Binding Site of HIV-1 Integrase by Proteolytic Peptide Mapping.
pp. 42-42(1)
Authors: Drake R.; Neamati N.; Sunthankar P.; Mazumder A.; Pommier Y.

Piperazinyloxoquinoline derivatives, potent and selective inhibitors of HIV-1 transcription
pp. 42-42(1)
Authors: Baba M.; Okamoto M.; Makino M.; Kimura Y.; Ikeuchi T.; Sakaguchi T.; Okamoto T.

A new antisense contruct for the genetic treatment of antigen-specific human lymphocytes an approach to adoptive immunotherapy of aids.
pp. 43-43(1)
Authors: Palu G.; Del Pup L.; Fenoglio D.; Li Pira G.; Saverino D.; Gimelli M.; De Giuli-Morghen C.; Manca F.

Design of Novel, Conformationally Restricted HIV Protease Inhibitors
pp. 43-43(1)
Authors: Tung R.D.; Salituro F.G.; Rao G.B.; Baker C.T.; Deininger D.D.; Li B.; Novak P.M.; Schairer W.C.; Court J.J.; Porter M.; Pazhanisamy S.

Nb-containing Polyoxometalate HIV-1 Protease Inhibitors.
pp. 43-43(1)
Authors: Hill C.I.; Judd D.A.; Tang J.; Nettles J.; Schinazi R.F.

Synthesis and In Vitro Antiviral Activity of Long-Chain 5'-(O-Alkoxycarbonylphosphinyl)-3'-azido-3'-deoxythymidines Against Drug-Sensitive and AZT- or PFA-Resistant Human Immunodeficiency Virus Type-1 (HIV-1)
pp. 43-43(1)
Authors: Rosowsky A.; Fu H.; Pai N.; Mellors J.W.; Richman D.D.; Hostetler K.Y.

Preliminary Efficacy, Pharmacokinetics and Safety of Repeated Multiple Doses of MKC-442 in HIV-Infected Volunteers
pp. 44-44(1)
Authors: Moxham C.; Borroto-Esoda K.; Noel D.; Furman P.; Szczech G.; Barry D.

Peptidomimetic Inhibitors of HCMV Protease
pp. 45-45(1)
Authors: Ogilvie W.; Abraham A.; Bailey M.; Bhavsar A.; Bonneau P.; Bordeleau J.; Bousquet Y.; Chabot C.; Duceppe J.-S.; Fazal G.; Goulet S.; Grand-Maitre C.; Guse I.; Halmos T.; Lavallee P.; Malenfant E.; O'Meara J.; Plante R.; Plouffe C.; Poirier M.; Poupart M.-A.; Soucy F.; Yoakim C.; Deziel R.

Structures of Herpes Virus Proteases: Exciting New Targets of Antiviral Drugs
pp. 45-45(1)
Authors: Qiu X.; Culp J.; Debouck C.; Hellmig B.; Hoog S.; Janson C.; O'Donnell K.; Smith W.; Abdel-Meguid S.

Interleukin-12 is a novel antiviral therapy
pp. 46-46(1)
Authors: Carr J.A.; Rogerson J.; Mulqueen M.J.; Booth R.F.G.; Roberts N.A.

(E)-2'-Deoxy-(fluoromethylene) Cytidine potently inhibits Replication of Human Cytomegalovirus Strains both Sensitive and Resistant to Ganciclovir and/or Foscarnet and Potentiates Antiviral Effects of Ganciclovir
pp. 46-46(1)
Authors: Cinatl J.; Vogel J.-U.; Cinatl J.; Rabenau H.; Doerr H.W.

In Vivo Anti-Cytomegalovirus (CMV) Activity and Safety of Oral Lobucavir in HIV Infected Patients
pp. 46-46(1)
Authors: Drew W.; Lalezari J.; Jordan C.; Jensen P.; Moe A.; Reynolds L.; Mohanty S.; Cross A.; Dunkle L.

2-Hydroxymethylcyclopropylidenemethylpurines and -pyrimidines - New Nucleoside Analogs with a Broad Spectrum Antiviral Activity
pp. 46-46(1)
Authors: Zemlicka J.; Qiu Y.-L.; Kern E.R.; Ptak R.G.; Breitenbach J.M.; Drach J.C.

Design and Biochemical Properties of Orally Active Inhibitors of Herpes Simplex Virus Thymidine Kinase
pp. 47-47(1)
Authors: Martin J.A.; Thomas G.J.; Lambert R.W.; Merrett J.H.; Parkes K.E.B.; Mulqueen M.; Kai-In P.W.; Roberts N.A.; Malcolm S.L.

Pharmacological properties of orally active inhibitors of Herpes simplex virus (HSV) thymidine kinase
pp. 47-47(1)
Authors: Mulqueen M.J.; Watkins A.M.; Dunford P.J.; Kai-In P.W.; Thomas G.; Lambert R.W.; Parkes K.E.B.; Merrett J.H.; Malcolm S.A.; Roberts N.A.; Martin J.A.

Mycophenolate mofetil markedly enhances the antiviral activity of acyclovir, ganciclovir and penciclovir against herpes simplex virus (wild type and TK strains) and human cytomegalovirus
pp. 47-47(1)
Authors: Neyts J.; De Clereq E.

Anti-Herpes Activities of 2-Thio-Pyrimidine Analogues.
pp. 47-47(1)
Authors: Shigeta S.; Kira T.; Mori S.; Saneyoshi M.

Disulfide-containing macrolides that inhibit a late stage of the replicative cycle of human immunodeficiency virus
pp. 48-48(1)
Authors: Witvrouw M.; Pannecolique C.; Balzarini J.; Jhaumeer-Laulloo S.; Pluymers W.; Este J.A.; Schols D.; Cherepanov P.; Schmit L.-C.; Debyser Z.; Vandamme A.M.; Desmyter J.; Ramadas S.R.; De Clereq E.

Novel isoforms of HIV-1 nef are expressed by frameshifting and selenium-dependent suppression of UGA termination codons.
pp. 48-48(1)
Authors: Taylor E.W.; Nadimpalli R.G.; Ramanathan C.S.; Dean R.G.; Hamilton J.A.; Thakur A.; Bumberg B.M.

AZT treatment of HIV-1-infected macrophages prevents apoptosis and necrosis in human astrocytic cells
pp. 49-49(1)
Authors: Perno C.; Aquaro S.; Panti S.; Balestra E.; Caroleo M.; Mastino A.; Cenci A.; Calio R.

Enhancement of the ion-pairing HPLC analysis of cellular 2'-deoxyadenosine 5'-triphosphate, 2',3'-dideoxyadenosine 5'-triphosphate and 2'-fluoro-2',3'-dideoxyadenosine 5'-triphosphate pools through periodate-treatment and fluorogenic derivatization
pp. 49-49(1)
Authors: Zhang H.; Hall B.; Kunder S.; Wood O.L.; Bacho M.A.; Ford H.; Papermaster S.; Black P.L.; Nielsen C.; Ussery M.A.

A Non-Human Primate Model for In Vivo Evaluation of Anti-HIV-1 Drugs.
pp. 49-49(1)
Authors: Rosenwirth B.; Bogers W.M.J.M.; Ueberla K.; Heeney J.L.

Antiretroviral Activity and Metabolism of bis(POC)PMPA, An Oral Bioavailable Prodrug of PMPA.
pp. 49-49(1)
Authors: Fridland A.; Robbins B.L.; Srinivas R.V.; Arimili M.; Kim C.; Bischofberger N.

Anti-retrovirus activity and pharmacokinetics in mice of bis(POC)-PMPA, the bis(isopropyloxycarbonyloxymethyl) oral prodrug of PMPA.
pp. 50-50(1)
Authors: Naesens L.; Bischofberger N.; Armilli M.; Kim C.; De Clercq E.

Line Probe Assay (LiPA) for HIV-1 RT: Prevalence of Drug-Selected Resistant Isolates in HIV-1 Infected VA Patients.
pp. 50-50(1)
Authors: Stuyver L.; Wyseur A.; Rombout A.; Rimland D.; Rossau R.; Schinazi R.F.

Phosphorylation of Zidovudine when Dosed in an In Vitro Pharmacodynamic System that Simulates In Vivo Pharmacokinetics.
pp. 50-50(1)
Authors: Hamzeh F.; Lee J.; Huber M.; Shahkolahi A.; Farzadegan H.; Wang G.; Lietman P.

Stavudine (d4T) and Didanosine (ddI) Combination Therapy in HIV-Infected Subjects: Analysis of Antiviral Effect and Safety in a Randomized Double-Blind Study
pp. 50-50(1)
Authors: Pollard R.; Peterson D.; Hardy D.; Pedneault L.; Rutkiewicz V.; Pottage J.; Murphy R.; Gathe J.; Beall G.; Skovronski J.; Cross A.; Dunkle L.

Identification of BMS-200,475 as a Novel and Potent Inhibitor of Hepatitis B Virus Replication
pp. 51-51(1)
Authors: Colonno R.J.; Innaimo S.F.; Seifer M.; Genovesi E.; Clark J.; Yamanaka G.; Hamatake R.; Terry B.; Standring D.; Bisacchi G.; Sundeen J.; Zahler R.

Synergistic Inhibition of In Vitro Hepadnaviral Replication by PMEA and Penciclovir or Lamivudine
pp. 51-51(1)
Authors: Shaw T.; Colledge D.; Locarnini S.A.

Reduced Replication Efficiency of 3TC-Resistant Human Hepatitis B Virus
pp. 52-52(1)
Authors: King R.W.; Ladner S.K.

Effect of -enantiomeric and racemic nucleoside analogues on mitochondrial functions in HEPG2 cells
pp. 52-52(1)
Authors: Sommadossi J.-P.; Schinazi R.F.; Gosselin G.; Imbach J.-L.; Chu C.K.; Lixin C.

Pharmacokinetic and Pharmacodynamic Studies of 1-(2-Fluoro-5-methyl--L-arabinofuranosyl) uracil (L-FMAU) in the Woodchuck Model of Hepatitis B Virus (HBV) Infection.
pp. 52-52(1)
Authors: Tennant B.; Jacob J.; Graham L.; Peek S.; Korba B.; Gerin J.; Witcher J.; Boudinot F.; Du J.; Chu C.

Effectiveness of Combination Therapies with 3TC, Famciclovir, and Alpha Interferon against Woodchuck Hepatitis Virus Replication in Chronically-infected Woodchucks: Model for Potential Anti-HBV Treatments.
pp. 52-52(1)
Authors: Korba B.; Baldwin B.; Cote P.; Schinazi R.; Gangemi D.; Gerin J.; Tennant B.

Comparison of the Viral Pharmacodynamics of 3TC in Chronically Infected Woodchucks and Humans.
pp. 53-53(1)
Authors: Hurwitz S.J.; Tennant B.; Korba B.E.; Schinazi R.F.

Antiviral Activity of Famciclovir Therapy on HBV Replication in Patients with Chronic Hepatitis B.
pp. 53-53(1)
Authors: Zoulim F.; Wang Z.; Pichoud C.; Trepo C.

Anti-HIV activity and metabolism of phosphoramidate derivatives of D4T-MP with variations in the amino acid moiety.
pp. 54-54(1)
Authors: Naesens L.; Cahard D.; Salgado A.; Bidois L.; De Clerco E.; McGuigan C.; Balzarini J.

QSAR Studies of Nucleoside Analogs with Anti-HIV Activity
pp. 54-54(1)
Authors: Tsai C.C.; McCabe K.J.; Durand P.J.; Lesniewski M.L.; Baker J.W.

Synthesis, Enzymology, and Anti-HIV Studies of Analogues of Isodideoxyadenosine and its Phosphorylated Derivatives
pp. 55-55(1)
Authors: Nair V.; Wenzel T.; Chao Q.; Jahnke T.S.

SAR and molecular modeling studies for the anti-HIV-1 activity optimization of pirryl-aryl-sulphones (PASs). Identification of derivatives with improved potency.
pp. 55-55(1)
Authors: Loi A.G.; Silvestri R.; Artico M.; Massa S.; Novellino E.; Greco G.; Ettorre A.; DeMontis A.; La Colla P.

Synthesis and Antiviral Evaluation of Benzyl-Substituted Thiopurine and Tiazofurin Derivatives
pp. 55-55(1)
Authors: Golankiewicz B.; Januszczyk P.; Padalko E.; Neyts J.; Balzarini J.; De Clereq E.

Targeting the HIV-1 Nucleocapsid Protein by Azodicarbonamide (ADA), Cystamine, and Dithiane Compounds
pp. 55-55(1)
Authors: Rice W.G.; Huang M.; McDonnell N.; Summers M.F.; Turpin J.A.

New 1,1,3-trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazine derivatives are potent and highly selective HIV-1 inhibitors targeted at the reverse transcriptase
pp. 56-56(1)
Authors: Witvrouw M.; Arranz M.E.; Pannecouque C.; Declercq R.; Jonckheere H.; Schmit J.-C.; Vandamme A.-M.; Diaz J.A.; Desmyter J.; Esnouf R.; Van Meervelt L.; Balzarini J.; Vega S.; De Clercq E.

In Vitro Anti-Human Immunodeficiency Virus (HIV) Activity of the Chromanone Derivative, 12-Oxocalanolide A
pp. 56-56(1)
Authors: Xu Z.-Q.; Flavin M.T.; Buckhett R.W.; Khilevich A.; Zembower D.E.; Roca-Acin J.

Betain-type fluoroalkylated oligomers are potent inhibitors of human immunodeficiency viruses type 1 (HIV-1) and other enveloped viruses
pp. 56-56(1)
Authors: Fujiwara M.; Okamoto M.; Mizuta T.; Hanasaki Y.; Ide T.; Katsuura K.; Sawada H.; Shigeta S.; Konno K.; Yokota T.; Baba M.

Highly Potent UC Analogs With Efficacy Against NNRTI-Resistant Viruses
pp. 56-56(1)
Authors: Buckheit R.W.; Fliakas-Boltz V.; Kinjerski T.I.; Russell J.D.; Pallansch L.A.

Mechanism of inhibition by piperazinyloxoquinoline derivatives as novel HIV-1 transcription inhibitors
pp. 57-57(1)
Authors: Okamoto M.; Suruga Y.; Makino M.; Kimura Y.; Ikeuchi T.; Sakaguchi T.; Okamoto T.; Baba M.

Human immunodeficiency virus gp120 as the primary target of action of AR177 (Zintevir)
pp. 57-57(1)
Authors: Este J.A.; Schols D.; Witvrouw M.; Cherepanov P.; Pannecouque C.; Rando R.F.; Debyser Z.; Desmyter J.; De Clercq E.

Inhibition of RRE-Rev interaction by RNA-binding polycations.
pp. 57-57(1)
Authors: Ke L.; Boykin D.W.; Kumar A.; Rigl C.T.; Wilson W.D.

The HIV-1 nef transframe protein has significant sequence and structural similarity to chemokines, as assessed by threading (inverse folding), sequence analysis, and molecular modeling.
pp. 57-57(1)
Authors: Nadimpalli R.G.; Zhang W.; Kececioglu J.; Taylor E.W.

Evaluation Of The Antiviral Activity And Cytotoxicity Of Nelfinavir In Combination With Reverse Transcriptase And Protease Inhibitors in an In Vitro Acute HIV-1 Infection Model.
pp. 58-58(1)
Authors: Bloom L.A.; Boritzki T.J.; Patick A.K.

The combination of Tat and NF-B inhibitor is more effective to suppress the HIV reactivation than either alone
pp. 58-58(1)
Authors: Kira T.; Hashimoto K.-i.; Okamoto T.; Baba M.; Shigeta S.

Three-drug combination of MKC-442, 3TC and AZT in vitro: Potential approach towards effective chemotherapy against HIV-1
pp. 58-58(1)
Authors: Piras G.; Nakade K.; Yuasa S.; Baba M.

The combined presence of the quinoxaline HBY097 and 3TC results in potent suppression of AZT-resistant HIV-1 strains
pp. 58-58(1)
Authors: Balzarini J.; Pelemans H.; Riess G.; Roesner M.; Winkler I.; De Clercq E.; Kleim J.-P.

Development of resistance to anti-HIV drugs in primary macrophages
pp. 59-59(1)
Authors: Perno C.; Aquaro S.; Cenci A.; Menzo S.; Clementi M.; Monque D.; Balestra E.; Calio R.

Kinetic Characterization of HIV-1 Reverse Transcriptases Carrying Mutations Shown to Confer Decreased Susceptibility to PMEA (Adefovir) in Vitro
pp. 59-59(1)
Authors: Cherrington J.M.; Mulato A.S.; Fuller M.D.; Cihlar T.; Chen M.S.

Anti-CD3/2-chloro-5-nitrobenzoic Acid Costimulation Differentially Enhances T-cell Growth Without Inducing HIV-1 Replication.
pp. 59-59(1)
Authors: Kinchington D.; Ng T.; Mathews N.; Tisdale M.; Devine D.; Ayuko W.O.

Decreased Thymidine Kinase-1 Activity in Vitro and in ex Vivo Stimulated PBMC'S of HIV-1 Patients Treated with Different Antiretroviral Agents
pp. 59-59(1)
Authors: Groschel B.; Zehner R.; Cinatl J.; Miller V.; Staszewski S.; Cinatl J.; Doerr H.W.

Altered Expression Of Inhibitory Cytokines, Interleukin-4 (IL-4) and Transforming Growth Factor-Beta1 (TGF1) In Bone Marrow Stromal Cells Induced By The Ecotropic Murine Leukemia Virus (MuLV)
pp. 60-60(1)
Authors: Oakley O.R.; Hughes N.K.; Gallicchio V.S.; Birch N.J.

Zidovudine Induces Alterations of Apoptosis and Resistance to Antineoplastic Agents in T-Cell Lymphoma Cells
pp. 60-60(1)
Authors: Kotchetkov R.; Groschel B.; Cinatl J.; Kornhuber B.; Rabenau H.; Cinatl J.

HIV-1 Tat Protein Potentiates Zidovudine-induced Bone Marrow Suppression.
pp. 60-60(1)
Authors: Agrawal K.C.; Chitnis S.; Mondal D.

Incorporation of Anti-HIV Nucleotide Analogs and Nucleoside Phosphonates into DNA by Human DNA Polymerases , and .
pp. 60-60(1)
Authors: Cihlar T.; Chen M.S.

Comparative Metabolism of the Antiviral Dimer AZT-P-ddl and the Monomers Zidovudine and Didanosine by Rat, Monkey and Human Hepatocytes
pp. 61-61(1)
Authors: Pan-Zhou X.-R.; Cretton-Scott E.; Zhou X.-J.; Xie M.-Y.; Rahmani R.; Schinazi R.F.; Duchin K.; Sommadossi J.-P.

Methylene Blue Viral Photo-inactivation is Associated with Formation of RNA-Protein Crosslinks.
pp. 61-61(1)
Authors: Floyd R.A.; Schneider J.E.; Lin X.-L.; Marble P.; Thomas T.; Pye Q.; Tang J.

Drug Delivery Via Amino Acid Phosphoramidates
pp. 61-61(1)
Author: Wagner C.R.

Identification and Characterization of Topical Microbicides: Inhibitors of HIV Sexual Transmission
pp. 61-61(1)
Authors: Halliday S.; Buckheit R.W.

Capture of HIV-1 gp120 and virions by lectin-immobilized polystyrene nanospheres: Potential approach toward prevention of HIV-1 infection
pp. 62-62(1)
Authors: Hayakawa T.; Niikawa T.; Kishida A.; Akashi M.; Baba M.

Topical and Combination Use of the Anti-HIV Phosphorothioate Oligonucleotide ISIS 5320
pp. 62-62(1)
Authors: Halliday S.M.; Russell J.D.; Wyatt J.R.; Ecker D.J.; Buckheit R.W.

Subcutaneous efficacy testing of two antisense oligonucleotides, HYB0184 and HYB0286, in SCID-hu-PBE Reconstituted HIV-Infected SCID mice
pp. 62-62(1)
Authors: Quenelle D.C.; Allen L.B.; Pallansch L.; Keith K.; Li S.; Wright K.; Triggs G.; Harris R.; Brazier A.; Agrawal S.

Efficacy, Pharmacokinetics and In Vivo Anti-HIV Activity of UC781
pp. 62-62(1)
Authors: Buckheit R.W.; Hollingshead M.; Stinson S.; Bader J.P.

Ribonucleotide Reductase Inhibitors, Didox and Trimidox, Demonstrate Antiretroviral Activity Alone or in Combination with DDI in a Murine Acquired Immunodeficiency (MAIDS) Model.
pp. 63-63(1)
Authors: Elford H.; Van't Riet B.; Mayhew C.; Oakley O.; Hughes N.; Piper J.; Gallicchio V.

Pharmacokinetic properties and toxicological studies of GP12A, a gene expression modulator and a potent antiviral agent against HIV-1 virus.
pp. 63-63(1)
Authors: Anazodo M.I.; Liu C.; Power C.; Duta E.; Friesen A.D.; Wainberg M.; Wright J.A.

Pentafuside (T-20), A Novel Inhibitor of HIV-1 Fusion: Pharmacokinetics in Rodents, Monkeys and Man.
pp. 63-63(1)
Authors: Venetta T.; DiMassimo B.; Johnson M.R.; Lambert D.M.; Recny M.A.; Hopkins S.; Saag M.

Synthesis and anti-HBV activity of 2'-fluoro--l-arabinofuranosyl purine nucleosides
pp. 63-63(1)
Authors: Ma T.; Lin J.-S.; Cheng Y.-C.; Chu C.K.

BMS-200475, a Novel Carbocyclic 2'-Deoxyguanosine Analog with Potent and Selective Anti-Hepatitis B Virus Activity in Vitro.
pp. 64-64(1)
Authors: Bisacchi G.S.; Sundeen J.E.; Slusarchyk W.A.; Rinehart K.; Innaimo S.; Chao S.; Jacobs G.; Young M.G.; Kocy O.; Merchant Z.; Egli P.; Lapointe P.; Daris J.P.; Martel A.; Colonno R.; Zahler R.

BMS-200,475, a New Anti-Hepatitis B Compound; Metabolic Studies and Comparison with 3TC, Penciclovir, and Lobucavir.
pp. 64-64(1)
Authors: Yamanaka G.; Wilson T.M.; Innaimo S.F.; Colonno R.J.

Arabinogalactan (9kDa)-araAMP, a Novel Liver-targeting Conjugate Inhibits Selectively HBV Replication in vitro.
pp. 64-64(1)
Authors: Cui L.; Faraj A.; Alaoui A.; Groman E.; Rutkowski J.; Josephson L.; Sommadossi J.-P.

Lamivudine and Penciclovir Act Synergistically as Inhibitors of In Vitro Hepadnaviral Replication Penciclovir
pp. 64-64(1)
Authors: Shaw T.; Colledge D.; Locarnini S.A.

Dual therapy with IL-12 and IFN provides a novel approach to the management of chronic viral disease.
pp. 65-65(1)
Authors: Carr J.A.; Rogerson J.; Pole D.; Mulqueen M.J.; Lamont A.; Roberts N.A.

Carbocyclic Guanosine Nucleoside BMS-200475 Treatment Inhibits Woodchuck Hepatitis Virus (WHV) Viremia in WHV-Carriers.
pp. 65-65(1)
Authors: Genovesi E.V.; Lamb L.M.; Medina I.; Clark J.M.; Taylor D.O.; Seifer M.; Innaimo S.; Standring D.N.; Sundeen J.E.; Bisacchi G.S.; Martel A.; Zahler R.; Colonno R.J.

Evaluation of the Antiviral Nucleoside, Lobucavir, in Chronically Woodchuck Hepatitis Virus (WHV) Infected Woodchucks.
pp. 65-65(1)
Authors: Medina; Clark J.M.; Lamb L.; Genovesi E.V.; Taylor D.; Standring D.; Seifer M.; Innaimo S.; Colonno R.J.

Comparative Activation of 2'-Deoxycytidine and Antiviral Oxathiolane Cytosine Nucleosides by Different Mammalian Liver Extracts.
pp. 65-65(1)
Authors: Schinazi R.F.; Hough L.; Juodawlkis A.; Marion P.; Tennant B.

Stereoselective Synthesis of 2' Fluorinated Nucleosides: A Novel Method for Stereoselective Introduction of Fluorine into Sugar Ring Precursors
pp. 66-66(1)
Authors: McAtee J.; Liotta D.C.

Effects of -D-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine 5'-triphosphate (-D-D4FC-TP) and its -L-enantiomer 5'-triphosphate (-L-D4FC-TP) on viral DNA polymerases.
pp. 66-66(1)
Authors: Faraj A.; Schinazi R.F.; Joudawlkis A.; Lesnikowski Z.; McMillan A.; Morrow C.D.; Sommadossi J.-P.

Use of Human Hepatocyte Primary Cultures to Evaluate the Cellular Pharmacology of Anti-hepatitis Agents.
pp. 66-66(1)
Authors: Cretton-Scott E.; Placidi L.; Martin L.T.; Sommadossi J.-P.

IgM anti-preS2 monitoring during combined corticosteroid/interferon alpha2b therapy in chronic hepatitis B.
pp. 66-66(1)
Authors: Sylvan S.; Fei G.; Yao G.; Hellstrom U.

Effect of indomethacin (INDO) on antiviral and immune response of peripheral blood mononuclear cells (PBMCs) from patients with chronic hepatitis B virus (HBV) infection.
pp. 67-67(1)
Authors: Andreone P.; Cursaro C.; Gramenzi A.; Buzzi A.; Di Giammarino L.; Miniero R.; Gasbarrini G.; Bernardi M.

Lack of Pharmacokinetic Interaction Between Dipyridamole and Zalcitabine in Rats.
pp. 67-67(1)
Authors: Abobo C.V.; Xian Y.

Pharmacokinetics of Dioxolane Guanine (DXG) Following Administration of DXG and Prodrug, (-)--D-2,6-Diaminopurine Dioxolane (DAPD), to Rats.
pp. 67-67(1)
Authors: Chen H.; Boudinot F.D.; Tang A.; Gao Z.; Schinazi R.F.; Chu C.K.

Pharmacokinetic Studies of Dipalmitoylphosphatidyl-2',3'-Dideoxy-3'-thiacytidine (DPP-3TC) in Rodents.
pp. 67-67(1)
Authors: Manouilov K.K.; Xu Z.-S.; Boudinot F.D.; Schinazi R.F.; Chu C.K.

Pharmacokinetics of (-)-2',3'-Dideoxy-5-Fluoro-3'-Thiacytidine [(-)-FTC] and its Metabolites in Rhesus Monkeys.
pp. 68-68(1)
Authors: Moore L.E.; Ni L.; Boudinot F.D.; McClure H.M.; Schinazi R.F.

Pharmacokinetics of -L-2',3'-dideoxy-5-Fluorocytidine in Rhesus Monkeys
pp. 68-68(1)
Authors: Martin L.T.; Cretton-Scott E.; Schinazi R.F.; McClure H.M.; Gosselin G.; Imbach J.-L.; Sommadossi J.-P.

Discovery of Antiviral Agents for Hepatitis C: Development of a High Throughput Assay for the NS3 Nucleoside Triphosphatase.
pp. 68-68(1)
Authors: August E.M.; Patnaude L.; Davis D.; Cryan J.; Yeh L.-A.

Development of a Hepatitis C Virus RNA Helicase High Throughput Assay
pp. 68-68(1)
Authors: Risano C.; Lee C.-G.; Sali D.; Chase R.; Hong Z.; Kwong A.D.

Hepatitis C Virus Infection in SCID Mice Using Xenografted Human Livers.
pp. 69-69(1)
Authors: Schinazi R.F.; Hough L.M.; Yao X.; Lloyd R.L.; Fallon M.; Sommadossi J.-P.; Fried M.W.; Mead J.R.

Effect of cidofovir on the tumor growth of SiHa (human cervical carcinoma) cells in nude mice
pp. 69-69(1)
Authors: Snoeck R.; Andrei G.; De Clercq E.

Enhanced Penetration of Acyclovir into Brain Tissue by RMP-7 in a Rat Model of Herpes Encephalitis.
pp. 70-70(1)
Authors: Kern E.R.; Bidanset D.; Rybak R.; Palmer J.; Bartus R.; Placidi L.; Sommadossi J.-P.

Combination of antiviral with anti-inflammatory preparations for the topical treatment for recurrent herpes simplex assessed using a zosteriform murine infection model.
pp. 70-70(1)
Authors: Awan A.R.; Flink O.; Harmenberg J.; Field H.J.

Interspecies Scale-Up of Antiviral Nucleoside Pharmacokinetics.
pp. 71-71(1)
Authors: Simmons P.T.; Boudinot F.D.

Evaluation of a Live Attenuated Recombinant Virus RAV 9395 as an HSV-2 Vaccine in Guinea Pigs.
pp. 71-71(1)
Authors: Spector F.C.; Kern E.R.; Palmer J.; Kaiwar R.; Spaete R.R.

Evaluation of Potential Treatments for Epstein-Barr Virus Infections in Man Using a Murine Gammaherpesvirus-68 Infection Model.
pp. 71-71(1)
Authors: Smee D.F.; Bailey K.W.; Sidwell R.W.

Identification of an Antisense Oligonucleotide with in vivo Activity Against Human Papillomavirus. 1. In vitro evaluation of oligonucleotides.
pp. 71-71(1)
Authors: Roberts P.C.; Frank B.L.; Boldt S.E.; Walther D.M.; Wolfe J.L.; Kilkuskie R.E.; Szymkowski D.E.; Greenfield I.M.; Sullivan V.; Mills J.S.

Identification of an Antisense Oligonucleotide with in vivo Activity Against Human Papillomavirus. 2. Efficacy against benign human genital condyloma in a mouse xenograft model.
pp. 72-72(1)
Authors: Lewis E.J.; Szymkowski D.E.; Greenfield I.M.; Kreider J.W.; Roberts P.C.; Frank B.L.; Wolfe J.L.; Kilkuskie R.E.; Mills J.S.

Cidofovir: induction of apoptosis in human papilloma virus (HPV)-containing cell lines
pp. 72-72(1)
Authors: Andrei G.; Snoeck R.; Piette J.; De Clercq E.

Preliminary results on the activity of cidofovir for the treatment of cervical intraepithelial neoplasia (CIN) grade III
pp. 72-72(1)
Authors: Snoeck R.; Arens M.; Muller C.; Noel J.C.; De Clercq E.; Bossens M.

A Comparative Study of the Use of the Herpchek^Tm Assay vs Viral Culture for the Detection of Labial Herpes Simplex Virus (HSV) in a Clinical Drug Trial.
pp. 72-72(1)
Authors: Sacks S.; Crosson P.; Doyle P.; Rennie B.; Berg J.; Gunnill L.; Gersten M.; Katz D.

A single sequence change destabilizes the influenza virus neuraminidase tetramer.
pp. 73-73(1)
Authors: Colacino J.M.; Garman E.; Chirgadze N.Y.; Staschke K.A.; Murti K.G.; Taylor G.; Air G.; Laver W.G.

GS 4071 Is a Potent and Selective Inhibitor of the Growth and Neuraminidase Activity of Influenza A and B Viruses In Vitro.
pp. 73-73(1)
Authors: Mendel D.B.; Tai C.Y.; Escarpe P.A.; Li W.-X.; Kim C.U.; Williams M.A.; Lew W.; Zhang L.; Bischofberger N.; Huffman J.H.; Sidwell R.W.; Chen M.S.

GS 4104 is A Highly Bioavailable Prodrug of the Novel, Potent Influenza Neuraminidase Inhibitor GS 4071.
pp. 74-74(1)
Authors: Li W.-X.; Escarpe P.A.; Chen M.S.; Lew W.; Williams M.; Zhang L.; Kim C.U.; Bischofberger N.; Cundy K.C.; Eisenberg E.J.; Mendel D.B.

In Vivo Influenza Virus-Inhibitory Activity of an Orally Administered Neuraminidase Inhibitor.
pp. 74-74(1)
Authors: Sidwell R.W.; Huffman J.H.; Bailey K.W.; Wong M.H.; Kim C.U.

Efficacy of GS 4104 in Ferrets Infected with Influenza A Virus.
pp. 74-74(1)
Authors: Kim C.U.; Bischofberger N.; Williams M.A.; Lew W.; Merson J.; Sweet C.

Efficacy of the Neuraminidase Inhibitor GG167 in the Treatment of Influenza Virus Infections.
pp. 74-74(1)
Authors: Hayden F.; Osterhaus A.; Treanor J.; Fleming D.; Aoki F.; Nicholson K.; Hirst H.; Keene O.; Wightman K.

Evaluation Of The Antiviral Activity And Cytotoxicity Of Peptidic Inhibitors Of Human Rhinovirus 3C Protease, A Novel Target For Antiviral Intervention.
pp. 75-75(1)
Authors: Patick A.K.; Ford C.; Binford S.; Fuhrman S.; Brothers M.; Meador J.; Webber S.E.; Okano K.; Zalman L.; Worland S.

Antirhinoviral Vinyl Acetylene Benzimidazoles
pp. 75-75(1)
Authors: Tebbe M.J.; Spitzer W.A.; Victor F.; Miller S.; Sattelberg T.; Tang J.; McKinney E.

Peptide analogs of the human parainfluenza virus fusion protein inhibit viral fusion and virus infection
pp. 75-75(1)
Authors: Qizhi Y.; Compans R.W.

Discovery of Peptide and Small Molecule Inhibitors of Paramyxovirus Fusion.
pp. 75-75(1)
Authors: Antczak J.; Sista P.; Merutka G.; Anwer M.; Lawless M.K.; Kang M.C.; Erickson J.; Johnson M.R.; Lambert D.M.

Antiviral activity of a novel compound P-4018 against different strains of herpes simplex virus in vitro and in vivo
pp. 76-76(1)
Authors: Andrei G.; Neyts J.; Snoeck R.; Sandvold M.L.; Myhren F.; De Clercq E.

Influence of Replacement of Oxygen with Sulfur at the 4'-Position on the Antiherpesviral Activities of Arabinofuranosyl Purine and Uracil Nucleosides
pp. 76-76(1)
Authors: Machida H.; Ashida N.; Miura S.; Watanabe M.; Yamada K.; Kitano K.; Yoshimura Y.

The Anti-Herpes Simplex Virus (HSV) Activity of n-Docosanol Includes Inhibition of the Viral Entry Process.
pp. 77-77(1)
Authors: Pope L.E.; Marcelletti J.F.; Parish M.L.; Spear P.G.; Katz D.H.

In Vitro Antiherpetic Activity Of Brivudin: Effect Of Variable Exposure Times And Evaluation Of Drug Interaction
pp. 77-77(1)
Authors: Iafrate E.M.; Ciucci A.; Manzini S.; Giachetti A.

Metabolism Of Brivudin (BVDU) In HSV-1 Infected Cells
pp. 77-77(1)
Authors: Ciucci A.; Iafrate E.M.; Giachetti A.

Anti-HSV-1 Activity of Phenolic Polymers Derived from p-Diphenolic Starting Compounds.
pp. 77-77(1)
Authors: Klocking R.; Helbig B.; Wutzler P.

In vitro and in vivo evaluation of the antiherpetic activity of a partially cyclized mu/nu-carrageenan.
pp. 78-78(1)
Authors: Pujol C.A.; Carlucci M.J.; Scolaro L.A.; Ciancia M.; Matulewicz M.C.; Cerezo A.S.; Damonte E.B.

The Inhibitory effect of nonionic surfactants on herpes simplex Type 2 replication in vitro.
pp. 78-78(1)
Authors: Reising S.; Bourne K.; Stanberry L.R.

Potent and selective inhibitors of Herpes simplex virus (HSV) thymidine kinase (TK) reduce reactivation of virus from latency in explanted ganglionic tissue in vitro
pp. 78-78(1)
Authors: Mulqueen M.J.; Watkins A.M.; Dunford P.J.; Wong P.K.-I.; Thomas G.; Lambert R.W.; Parkes K.E.B.; Merrett J.H.; Malcolm S.A.; Roberts N.A.; Martin J.A.

Rapid Method for Plaque Enumeration in Herpes Plaque Reduction Assays.
pp. 78-78(1)
Authors: Hodges-Savola C.A.; Werness L.M.; Henry S.L.; Walker C.L.; Wetherall N.T.

Phenotypic and Genotypic Characterization of Acyclovir Resistant Herpes Simplex Virus.
pp. 79-79(1)
Authors: Lawrence W.; Peele T.; Hill E.

Genotypic characterization of various herpes simplex virus type 1 (HSV-1) clones resistant to acyclic nucleoside phosphonates
pp. 79-79(1)
Authors: Andrei G.; Snoeck R.; De Clereq E.; Fiten P.; Opdenakker G.

Proteolytic, Active-Site Mapping of Herpesvirus Thymidine Kinases Type 1 and 2 Photolabeled with Thymidine and Ganciclovir Photoaffinity Analogs.
pp. 79-79(1)
Authors: Drake R.; Rechtin T.; Hume S.; Black M.

Induction of genetic damage and apoptosis by ganciclovir in Chinese Hamster Ovary cells transfected with the thymidine kinase (tk) gene of HSV-1
pp. 79-79(1)
Authors: Thust R.; Kaina B.; Klocking R.; Wutzler P.

Foscarnet Inhibits Differentiation of Osteoblasts in Vitro.
pp. 80-80(1)
Authors: Titus L.; Boden S.D.; Hair G.; Racine M.; Schinazi R.F.

Viral thymidine kinase is essential for the spread of herpes simplex virus (HSV) induced zosteriform lesions in vivo.
pp. 80-80(1)
Authors: Mulqueen M.J.; Watkins A.M.; Dunford P.J.; Kai-In P.W.; Thomas G.; Lambert R.W.; Parkes K.E.B.; Merrett J.H.; Malcolm S.A.; Roberts N.A.; Martin J.A.

The Relationship of Basal Cell Layer Drug Concentration (C^*) to the Antiviral Efficacy: A Rigorous Evaluation of the C^* Concept for Predicting the Entire Range of Topical Efficacy of Acyclovir Formulations in the Treatment of Cutaneous HSV-1 Infections in Hairless Mice.
pp. 80-80(1)
Authors: Mehta S.C.; Afouna M.I.; Ghanem A.-H.; Higuchi W.I.; Kern E.R.; El-Shattawy H.

The Antiviral Efficacy of Topical ZOVIRAX(R) Cream or VECTAVIR(R) Cream in HSV-Infected Mice.
pp. 80-80(1)
Authors: Selleseth D.W.; Johnson J.R.; Davis G.

Herpes Simplex virus in the mouse: zosteriform lesions with adoptive transfer of immune cells: a model which mimics human recurrent disease.
pp. 81-81(1)
Authors: Awan A.R.; Harmenberg J.; Field H.J.

Further Investigation into the Recurrence of Infectious Virus in the Nervous System of Mice Infected with HSV-1 on Cessation of Valaciclovir Therapy.
pp. 81-81(1)
Authors: Thackray A.M.; Field H.J.

Evaluation of the antiviral activity of an organomatallic compound in the guinea pig model of genital herpes.
pp. 81-81(1)
Authors: Bourne N.; Stanberry L.

Effect of Prophylactic and Therapeutic Administration of Topical 9-[2-(phosphonomethoxy)ethyl]guanine (PMEG) in Genital Herpes Simplex Virus (HSV) Infections of Guinea Pigs.
pp. 81-81(1)
Authors: Palmer J.; Harden E.; Hartline C.; Kern E.R.

The relative antiviral efficacy of twice daily cidofovir versus acyclovir and trifluridine in the HSV-1/NZ rabbit keratitis model
pp. 82-82(1)
Authors: Gordon Y.J.; Romanowski E.G.

Evaluation of Liposome-encapsulated Foscarnet in the Rabbit Eye.
pp. 82-82(1)
Authors: Hoffmann F.; Gumbel H.; Stieneker F.; Kreuter J.; Cinatl J.; Cinatl J.

Inhibition of Human Cytomegalovirus by PMEA.
pp. 82-82(1)
Authors: Xiong X.; Flores C.; Cherrington J.M.; Fuller M.D.; Mendel D.B.; Moon K.; Chen M.S.

Individual Pre-screening of Antiviral Substances Using CYTOMORPH-b
pp. 82-82(1)
Authors: Klocking R.; Wonne J.; Wutzler P.

Inhibition of cytomegalovirus by metal chelators: investigations on metabolic pathways
pp. 83-83(1)
Authors: Scholz M.; Pioch K.; Vogel J.-U.; Prosch S.; Cinatl J.; Doerr H.

Synthesis and Isomeric Assignment of 2-Hydroxymethylcyclopropylidenepurines and -pyrimidines- New Antiviral Agents.
pp. 83-83(1)
Authors: Qiu Y.-L.; Zemlicka J.

Selective Activity of 2-Hydroxymethylcyclopropylidenemethyl Purines Against Human Cytomegalovirus.
pp. 83-83(1)
Authors: Drach J.C.; Fan B.Y.; Ptak R.G.; Breitenbach J.M.; Borysko K.Z.; Qiu Y.-L.; Zemlicka J.

Coupled in vitro Transcription/Translation as a Tool for the Study of Human Cytomegalovirus DNA Polymerase.
pp. 83-83(1)
Authors: Cihlar T.; Cherrington J.M.

Ganciclovir (GCV) resistance due to a new mutation in the UL97 gene product in a HCMV isolate from an AIDS patient.
pp. 84-84(1)
Authors: Baldanti F.; Sarasini A.; Simoncini L.; Zavattoni M.; Gatti M.; Underwood M.; Biron K.K.; Gerna G.

Ganciclovir (GCV) resistance caused by oral GCV in an heart transplant recipient with multiple HCMV strains in blood.
pp. 84-84(1)
Authors: Baldanti F.; Zavattoni M.; Simoncini L.; Chiesa A.; Grossi P.; Underwood M.; Biron K.K.; Gerna G.

Dose and Treatment Duration-Dependence of Ganciclovir Against Murine Cytomegalovirus Infection in Severe Combined Immunodeficient Mice--Experimental and Clinical Implications
pp. 84-84(1)
Authors: Duan J.; Paris W.; Kibler P.; Bousquet C.; Liuzzi M.; Cordingley M.G.

Lethal Hepatitis During Acute MCMV Infection: Analysis and Treatment With Ganciclovir and HPMPC.
pp. 84-84(1)
Authors: Bolger G.; Lapeyre N.; Garneau M.; Rheaume M.; Kibler P.; Bousquet C.; Cordingley M.G.

SCID-hu Thy/Liv Mouse Model for In Vivo Human CMV Antiviral Evaluation.
pp. 85-85(1)
Authors: Stoddart C.A.; Bogan M.R.; Moreno M.E.; Linquist V.D.; Warren S.; McCune J.M.

Cyclic HPMPC is safe and highly effective against guinea pig cytomegalovirus infection in immunocompromised animals.
pp. 85-85(1)
Authors: Bourne N.; Hitchcock M.; Bernstein D.

Development of An Elisa Assay for Determining Antiviral Activity Against Epstein-Barr Virus Replication.
pp. 85-85(1)
Authors: Marshall G.; Kern E.R.

Activity of benzimidazole riboside 1263W94 (5,6-dichloro-2-(isopropylamino)-1--L-ribofuranosyl-1H-benzimidazole) against Epstein-Barr Virus
pp. 85-85(1)
Authors: Zacny V.L.; Davis M.G.; Biron K.K.; Pagano J.S.

A New Class of Carbocyclic Influenza Neuraminidase Inhibitors: Structure-Activity Relationships.
pp. 86-86(1)
Authors: Williams M.A.; Kim C.U.; Lew W.; Liu H.; Chen M.S.; Mendel D.; Li W.; Tai L.; Escarpe P.; Swaminathan S.; Bischofberger N.; Stevens R.C.; Laver W.G.

GS 4104: A Highly Potent Orally Bioavailable Influenza Neuraminidase Inhibitor.
pp. 86-86(1)
Authors: Williams M.A.; Kim C.U.; Lew W.; Zhang L.; Swaminathan S.; Bischofberger N.; Chen M.S.; Mendel D.; Li W.; Tai L.; Escarpe P.; Cundy K.C.; Eisenberg E.J.; Lacy S.; Sidwell R.W.; Stevens R.C.; Laver W.G.

In Vitro Activity of the Neuraminidase Inhibitor GS4071 Against Influenza Viruses.
pp. 86-86(1)
Authors: Hayden F.; Rollins B.

Characterization of influenza A viruses that are resistant to a fusion inhibitor related to podocarpic acid.
pp. 86-86(1)
Authors: Staschke K.A.; Hatch S.D.; Tang J.C.; Hornback W.J.; Munroe J.E.; Colacino J.M.; Muesing M.A.

Antiviral Activity of C-2 Analogs of Enviroxime. An Exploration of the Role of Critical Functionality.
pp. 87-87(1)
Authors: Spitzer W.A.; Victor F.; Loncharich R.; Tang J.

Antiviral Activity, and Biological Properties of Vinylacetylene Analogs of Enviroxime
pp. 87-87(1)
Authors: Spitzer W.A.; Victor F.; Brown T.J.; Campanale K.; Heinz B.A.; Shipley L.A.; Su K.S.; Tang J.; Vance L.M.

Differential antiviral activity of several IMP dehydrogenase inhibitors
pp. 87-87(1)
Authors: Neyts J.; Andrei G.; De Clereq E.

Aniti-influenza virus activity by circular dumbbell RNA/DNA chimeric oligo-nucleotides
pp. 87-87(1)
Authors: Yamakawa H.; Ishibashi T.; Abe T.; Hatta T.; Takai K.; Takaku H.

Inhibitory Effect of Hirsutine on Influenza Virus Replication In Vitro.
pp. 88-88(1)
Authors: Konno K.; Inoue H.; Fujiwara M.; Mizuta T.; Takayama H.; limura Y.; Aimi N.; Tokuhisa K.; Hanasaki Y.; Katsuura K.; Shigeta S.; Yokota T.

Effects of Viramid in Treatment of Influenza
pp. 88-88(1)
Authors: Kubar O.; Bichurina M.; Stepanova L.; Shamanova M.; Isakov V.; Rikov A.; Lobzin U.

In Vitro and In Vivo Effects of RD3-0028 against Respiratory Syncytial Virus
pp. 88-88(1)
Authors: Sudo K.; Watanabe W.; Watanabe S.; Sato R.; Kajiyashiki T.; Konno K.; Shigeta S.; Yokota T.

Anti-Respiratory Syncytial Virus Activity of Dendrimer Polyanions.
pp. 88-88(1)
Authors: Barnard D.L.; Sidwell R.W.; Gage T.L.; Okleberry K.M.; Matthews B.; Holan G.

Anti-Respiratory Syncytial Virus (RSV) Activity Of 2-5a Antisense Oligonucleotide Chimeras.
pp. 89-89(1)
Authors: Barnard D.L.; Sidwell R.W.; Matheson J.E.; Xiao W.; Player M.; Torrence P.F.

Effect of Neutralizing Antibody and Interferon on Antibody Resistant Mutants of Poliovirus.
pp. 89-89(1)
Authors: Langford M.P.; Crainic R.; Mosser A.G.

Oral Bioavailability Screening of the Antirhinoviral Vinyl Acetylene Benzimidazoles
pp. 89-89(1)
Authors: Tebbe M.J.; Spitzer W.A.; Tang J.

A Novel Anti-Rhinoviral Compound Directed at 3C Protease can Diminish IL-6 and IL-8 Production in a Transformed Bronchial Epithelial Cell Line
pp. 89-89(1)
Authors: Zalman L.S.; Brothers M.A.; Okano K.; Webber S.E.

Rhinovirus 3C Protease Inhibitors Are Efficacious Against Several Related Picornaviruses
pp. 90-90(1)
Authors: Ford C.; Binford S.; Fuhrman S.; Webber S.E.; Okano K.; Patick A.K.

In Vitro Isolation And Characterization Of A Human Rhinovirus Variant Resistant To A 3C Protease Inhibitor
pp. 90-90(1)
Authors: Binford S.; Ford C.; Fuhrman S.; Webber S.E.; Okano K.; Patiek A.K.

Studies on Antiviral Effect of Extract from Alternanthera philoxeroides Griseb on Epidemic Hemorrhagic Fever Virus in Vivo
pp. 90-90(1)
Authors: Peng H.; Qu C.; Yang Z.; Liu Y.

Inhibition of Pestivirus (BVDV) Replication by a Cyclic Urea Derivative
pp. 90-90(1)
Authors: Galabov A.S.; Uzunov S.; Abashev Y.; Wassilewa I.

Treatment Of Lethal Lassa Virus Infection In Experimental Animal Model With Anti-TNF- Serum
pp. 91-91(1)
Authors: Ignatyev G.M.; Kaliberov S.A.; Kaschentseva E.A.

Inactivation of Enveloped and Non-Enveloped Viruses by Ozone Induced Oxidative Stress
pp. 91-91(1)
Authors: Lea P.; Klein D.; Lee L.; Adachi D.; Dermott W.J.

Recognition and stabilization of single stranded adenine sequences by thymine base substituted-naphthalene diimide
pp. 91-91(1)
Authors: Takenaka S.; Takagi M.; Yokoyama M.; Kondo H.

Substrate Specificity of HCV NS3 Protease Analyzed With Modified Peptide Substrates
pp. 92-92(1)
Authors: Tsiang M.; Toole J.J.; Lee D.W.; Jain A.K.; Xiong S.; Flores C.; Smith J.L.; Gibbs C.S.

Purification and Characterization of Hepatitis C Virus NS3 Helicase Activity
pp. 92-92(1)
Authors: Chase R.; Lee C.-G.; Ferrari E.; Wright-Minogue J.; Chen J.; Risano C.; Sali D.; Hong Z.; Kwong A.D.

Characterization of recombinant hepatitis C virus NS5B gene product (RDRP)
pp. 93-93(1)
Authors: Hagedorn C.; Al R.; De Staercke C.; Wang Y.; Xie Y.

Characterization of A Novel Fusion Inhibitor of Influenza A Virus
pp. 93-93(1)
Authors: Luo G.-X.; Torri A.; Cianci C.; Danetz S.; Tiley L.; Harte B.; Yu K.-L.; Meanwell N.; Colonno R.; Krystal M.